Cantor Fitzgerald analyst Kristen Kluska reiterates an Overweight rating on PolarityTE with a $13 price target. On January 9, a publication featuring the use of SkinTE was published in Plastic Surgery Case Studies, and on January 13, an interview regarding separate use of SkinTE was published in Utah Business, Kluska tells investors in a research note. These case studies demonstrate the positive effects of SkinTE as a first-line therapy in large wounds, an effective solution where other invasive surgical techniques have failed, also in large wounds, and the functionality component of SkinTE, contends the analyst.